Amarin Corp Plc (AMRN)

[ziploc_1]

The problem is that there too many potential culprits in cases where generics use off label prescriptions to infringe.

This makes it difficult for an innovating company to pursue a generic company for infringement on their patented indication

The parties to blame may include:

-the generic company
-the Doc
-the patient
-the pharmacy
- the pharmacy benefit plan
-the insurance company
-the government

A generic company may invest very little cash, and even though their infringing product may be inferior to the branded product... they can still stand to make lucrative profits.